Nektar Therapeutics
455 Mission Bay Blvd South
San Francisco
California
94158
United States
Tel: 415-482-5300
Website: http://www.nektar.com/
Email: iaffairs@nektar.com
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
462 articles with Nektar Therapeutics
-
Nektar Therapeutics Reports Third Quarter 2021 Financial Results
11/4/2021
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2021 .
-
Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial Markets
10/26/2021
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S.-based financial markets.
-
Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study
9/21/2021
Nektar Therapeutics (NASDAQ: NKTR) announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255, Nektar's interleukin-15 (IL-15) receptor agonist, in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma (UC) in the Phase II JAVELIN Bladder Medley study.
-
Nektar collaborates with Pfizer and Merck KGaA, Darmstadt, Germany, to assess NKTR-255 in combination with Bavencio in patients with bladder cancer.
-
The top three clusters from last year's list - Greater Boston, San Francisco Bay Area and San Diego - all stood their ground and maintained their rankings from the previous year.
-
Asher Bio began two years ago and raised $55 million in a Series A financing round this March to take forward a series of engineered cytokines that aim to eliminate both the toxicities and the loss of efficacy in immunotherapy.
-
Nektar Therapeutics Reports Second Quarter 2021 Financial Results
8/5/2021
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2021.
-
Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets
7/27/2021
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2021 on Thursday, August 5, 2021, after the close of U.S.-based financial markets.
-
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex
7/22/2021
RedHill Biopharma Ltd. today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca") and Nektar Therapeutics have entered into a settlement and license agreement with Apotex, Inc. resolving their patent litigation.
-
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
7/19/2021
Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer (CMO).
-
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
6/7/2021
Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time .
-
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity
5/20/2021
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a first-in-class, composition of stable PEG conjugates of native IL-2 designed to selectively stimulate T regulatory (Treg) cell function
-
Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)
5/18/2021
-- Results demonstrate NKTR-255's differentiated pharmacologic profile versus precomplexed IL-15 agonists, supporting its potential as a potent immunotherapy agent --
-
London-based venture capital fund Abingworth closed on a new Clinical Co-Development Fund now at $582 million. The fund's original target was just at $350 million.
-
Nektar Therapeutics Reports First Quarter 2021 Financial Results
5/6/2021
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2021.
-
Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets
4/27/2021
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2021 on Thursday, May 6, 2021, after the close of U.S.-based financial markets.
-
Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
2/25/2021
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2020.
-
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets
2/18/2021
Nektar Therapeutics will announce its financial results for the fourth quarter and year-ended December 31, 2020, on Thursday, February 25, 2021, after the close of U.S.-based financial markets.
-
Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer
2/17/2021
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin
-
Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
2/17/2021
Nektar Therapeutics (NASDAQ: NKTR) announced today that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada ) for a Phase 2/3 study of bempegaldesleukin (NKTR-214, BEMPEG)